Capio Biosciences and BioView Ltd Announce Collaboration to Develop Integrated Workflow for Sample to Answer Assay of Circulating Tumor Cells
Capio Biosciences, a biotech start-up, which is developing a platform for the capture of circulating tumor cells (CTCs) from whole blood, and BioView Ltd. (TASE:BIOV), a leader in the application of automated cell imaging and analysis solutions for Liquid Biopsy applications, are proud to announce a collaboration to explore the integration of the two technologies for the development of a Liquid Biopsy- CTC, sample to answer clinical assay.
Circulating tumor cells (CTCs) have received a great deal of scientific and clinical attention as a biomarker for diagnosis, prognosis and therapy selection of many types of cancers. Given their potential significance in clinical application, a variety of detection methods, utilizing the recent advances in nanotechnology and microfluidics, have been introduced in an effort of achieving clinically significant detection of CTCs. However, effective detection, isolation and characterization of CTCs still remain a tremendous challenge due to their extreme rarity and phenotypic heterogeneity.
Capio Biosciences has introduced a unique, innovative approach that takes advantage of naturally occurring processes achievable through application of nanotechnology to realize significant improvement in sensitivity and specificity of CTC capture.
Capio Biosciences and BioView agreed to launch a joint study to evaluate the performance of an integrated solution of clinical utility making use of Capio Bioscience’s CapioCyteTM and BioView’s DeNovoTM systems for the detection and characterization of tumor cells originating from prostate cancer stained with specific tumor related biomarkers.
The study will be led by Dr. Seungpyo Hong, co-founder and President of Capio, under a Fee for Service (FFS) agreement with the University of Wisconsin.
“We are delighted to collaborate with BioView to co-develop this promising assay that will allow us to be steps closer to bring our liquid biopsy technology to the clinic.”, said Dr. Hong, Capio Bioscience President.
“We are excited to be collaborating with Capio Biosciences and see great potential for the combination of the two technologies”, said Dr. Alan Schwebel, BioView CEO. “The collaboration between the companies is a result of the realization that in order for CTCs to have true clinical utility, focused efforts should be made to introduce an automated, high-throughput integrated - holistic back and front-end solution that is standardized, easy to operate and offers significant clinical utility for both the patient and health provider.
About Capio Biosciences:
Founded in 2015 by cofounders Seungpyo Hong PhD (UW, Madison, WI) and Andrew Wang MD (UNC, Chapel Hill, NC), Capio Biosciences is a biotech start-up focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes.
Dr. Hong, Milton J. Henrichs Chair Professor of Pharmaceutical Sciences and Director of Wisconsin Center for NanoBioSystems at the University of Wisconsin and President and cofounder of Capio Biosciences, Inc., obtained his Ph.D. in Macromolecular Science and Engineering at the University of Michigan in 2006.
Dr. Wang, is Professor and Associate Chair of Research in the department of Radiation Oncology at the University of North Carolina (UNC) School of Medicine and CEO and cofounder of Capio Biosciences Inc. As of 8/24, he will serve as Kenneth Pye Professor of Cancer Research, Associate Vice Chair of Translational Research, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas TX
Capio Biosciences has developed the CapioCyte™ system. The CapioCyte system makes use of proprietary technology for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater sensitivity than other platforms currently available. For more information about the CapioCyte technology, and press related issues, please contact [email protected] or visit our website at www.capiobiosciences.com
About BioView technology:
Established in 2000, and led by an expert team of biologists, software engineers and physicists, BioView develops, manufactures and supplies cell imaging equipment, and analysis software to medical institutes and universities. BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact [email protected] or visit our website at www.bioview.com/denovo .
BioView’s state of the art DeNovo imaging and analysis system automates the detection and characterization of CTC utilizing advanced rapid 3D imaging as well as AI based deep learning analysis algorithms developed in collaboration with leading cancer research centers worldwide. With a small footprint and touchless automation, DeNovo harnesses the best in engineering to deliver the most functionality, efficiency, and reliability. Flexible, accurate, and a breeze to operate, BioView’s DeNovo system facilitates the introduction of liquid biopsy to clinical practice.